| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CNOT7 |
| Uniprot No | Q9UIV1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-285aa |
| 氨基酸序列 | MPAATVDHSQRICEVWACNLDEEMKKIRQVIRKYNYVAMDTEFPGVVARPIGEFRSNADYQYQLLRCNVDLLKIIQLGLTFMNEQGEYPPGTSTWQFNFKFNLTEDMYAQDSIELLTTSGIQFKKHEEEGIETQYFAELLMTSGVVLCEGVKWLSFHSGYDFGYLIKILTNSNLPEEELDFFEILRLFFPVIYDVKYLMKSCKNLKGGLQEVAEQLELERIGPQHQAGSDSLLTGMAFFKMREMFFEDHIDDAKYCGHLYGLGSGSSYVQNGTGNAYEEEANKQS |
| 预测分子量 | 36.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CNOT7重组蛋白的参考文献，信息基于已有研究领域整理：
1. **文献名称**：*CNOT7 regulates the proliferation and apoptosis of hepatocellular carcinoma cells through the PI3K/Akt pathway*
**作者**：Li, X. et al.
**摘要**：研究发现CNOT7在肝癌组织中高表达，通过调控PI3K/Akt信号通路促进肿瘤细胞增殖并抑制凋亡，提示其作为潜在治疗靶点。
2. **文献名称**：*The CCR4-NOT deadenylase complex controls mRNA stability and cell viability via CNOT7*
**作者**：Yamashita, A. et al.
**摘要**：阐明CNOT7作为CCR4-NOT复合体核心亚基，通过脱腺苷酸化调控靶mRNA降解，影响细胞周期进程及生存能力。
3. **文献名称**：*CNOT7 knockout impairs DNA damage response and promotes genomic instability*
**作者**：Chen, Y. et al.
**摘要**：证明CNOT7缺失导致DNA损伤修复能力下降，增加基因组不稳定性，揭示其在维持基因组完整性中的关键作用。
(注：以上为模拟文献示例，实际研究需通过数据库如PubMed检索确认。)
The CCR4-NOT complex is a conserved multi-protein assembly critical for post-transcriptional gene regulation, including mRNA deadenylation, decay, and translational repression. CNOT7 (also known as CAF1), a core subunit of this complex, encodes a deadenylase enzyme that catalyzes the removal of poly(A) tails from mRNAs, marking them for degradation or storage. It interacts with other subunits like CNOT1. CNOT2/3. and CNOT6/6L to mediate sequence-specific mRNA regulation, often guided by RNA-binding proteins or non-coding RNAs. CNOT7's enzymatic activity influences diverse cellular processes, such as development, stress responses, and immune regulation, with dysregulation linked to cancer, neurodegeneration, and metabolic disorders.
Recombinant CNOT7 protein is engineered for in vitro studies to dissect its structural and functional roles. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), it retains deadenylase activity and binding capacity for partner proteins or RNAs. Researchers use purified CNOT7 to investigate its catalytic mechanisms, substrate specificity, and interactions within the CCR4-NOT complex. Structural studies reveal its N-terminal catalytic domain (Mg²⁺-dependent exonuclease fold) and C-terminal region involved in protein-protein interactions. Additionally, recombinant CNOT7 serves as a tool to screen inhibitors targeting its enzymatic activity, with therapeutic potential in diseases driven by aberrant mRNA stability. Its study also clarifies post-transcriptional regulatory networks, aiding the development of RNA-centric therapies.
×
